Mark Mahaney, Evercore ISI head of internet research, joins 'Squawk Box' to discuss news of Netflix shares hitting all-time ...

The stock market (SP500), (DJI), (COMP:IND) is due for a pause following a “massive blowout” earnings rally in May, according ...

On May 30, Evercore ISI downgraded Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT )’s stock from an “Outperform” rating to “In ...

June could provide an opportunity for investors according to Evercore ISI with the Fed expected to lower interest rates and ...

Evercore ISI, an independent investment banking advisory and research firm, highlights a significant shift in the insurance ...

On Thursday, Evercore ISI analysts lowered the price target for Brown Forman (NYSE:BFb) (NYSE:BF-B) stock to $30 from $38, maintaining an In Line rating. The decision comes after the company’s ...

With the S&P 500 Index setting record after record, Evercore ISI is predicting another double-digit rally through the end of 2024. Julian Emanuel, the firm’s chief equity and quantitative ...

Evercore ISI also resumed coverage of Viper Energy with an Outperform rating, emphasizing the company’s ability to maintain its 2025 volume guidance amid reduced activity from its parent company.

NEW YORK (Reuters) - Evercore ISI on Wednesday forecast the S&P 500 will rise to 6,600 by mid-2025, saying a "decisive and uncontested" win by Donald Trump as U.S. president and a potential ...

Evercore ISI analysts pointed out that Apple Inc. (NASDAQ:AAPL) is likely to introduce its foundation models to app ...

Evercore ISI analyst Gavin Clark-Gartner initiated coverage with a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and set a price target of $68.00. The company’s shares ...

Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (EDIT) to Outperform from In Line with a price target of $7, up from $3. Editas has $322M in cash including the recent DRI royalty deal ...